Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.
Behavioural symptoms of Alzheimer's disease, such as aggression, may determine the care patients required. Most postmortem neurochemical studies have been of institutionalized patients and conclusions drawn from these may not be valid for all patients. We have shown that serotonin 2 receptors are not lost from 12 of the 13 areas of cerebral cortex examined in the patients assessed to be free of aggressive symptoms. This has been interpreted as representing the relative preservation of cortical interneurones. In contrast choline acetyltransferase activity was reduced in all areas whereas serotonin content was reduced in only 2 of the 4 areas examined.
Procter
A W
AW
Miriam Marks Department of Neurochemistry, Institute of Neurology, London.
Francis
P T
PT
Stratmann
G C
GC
Bowen
D M
DM
D000368:Aged; D000369:Aged, 80 and over; D000374:Aggression / Q000502:physiology*; D000544:Alzheimer Disease / Q000378:metabolism / Q000523:psychology*; D015415:Biomarkers / Q000737:chemistry; D002540:Cerebral Cortex / Q000737:chemistry*; D002795:Choline O-Acetyltransferase / Q000032:analysis; D006801:Humans; D007395:Interneurons / Q000378:metabolism; D008875:Middle Aged; D010455:Peptides / Q000032:analysis; D011869:Radioligand Assay; D012189:Retrospective Studies; D012701:Serotonin / Q000032:analysis*; D013004:Somatostatin; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D015415:Biomarkers; D010455:Peptides; C029993:somatostatin-like peptides; D012701:Serotonin; D013004:Somatostatin; D005680:gamma-Aminobutyric Acid; D002795:Choline O-Acetyltransferase